Johnson & Johnson (NYSE:JNJ) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Johnson & Johnson has a consensus rating of "Moderate Buy" from 20 brokerage firms, with nine analysts giving it a buy rating and nine a hold rating.
• The company's shares opened at $179.10, with a market capitalization of $431.33 billion and a reported revenue of $23.74 billion for the last quarter, exceeding analysts' expectations.
• Johnson & Johnson declared a quarterly dividend of $1.30 per share, with an annual yield of 2.9%, set to be paid on September 9th.

Johnson & Johnson (NYSE:JNJ - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twenty ratings firms that are presently covering the company, MarketBeat.com reports. Nine investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $176.2857.

Several analysts recently commented on JNJ shares. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Citigroup boosted their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a report on Thursday. Barclays boosted their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. UBS Group boosted their price target on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a report on Thursday, July 17th. Finally, Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $179.0980 on Monday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.16. The firm has a market capitalization of $431.33 billion, a P/E ratio of 19.15, a PEG ratio of 2.28 and a beta of 0.41. The business has a fifty day moving average of $163.48 and a 200 day moving average of $159.30.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the previous year, the company posted $2.82 earnings per share. Johnson & Johnson's revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Hedge Funds Weigh In On Johnson & Johnson

Several large investors have recently made changes to their positions in the business. Carter Financial Group INC. purchased a new position in shares of Johnson & Johnson in the second quarter valued at about $288,000. Cim Investment Management Inc. lifted its position in shares of Johnson & Johnson by 99.6% in the second quarter. Cim Investment Management Inc. now owns 13,978 shares of the company's stock valued at $2,078,000 after acquiring an additional 6,976 shares in the last quarter. Clarion Wealth Managment Partners LLC purchased a new position in shares of Johnson & Johnson in the second quarter valued at about $1,196,000. Monarch Capital Management Inc. lifted its position in shares of Johnson & Johnson by 0.7% in the second quarter. Monarch Capital Management Inc. now owns 62,282 shares of the company's stock valued at $9,514,000 after acquiring an additional 426 shares in the last quarter. Finally, North Dallas Bank & Trust Co. purchased a new position in shares of Johnson & Johnson in the second quarter valued at about $2,274,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.